Skip to content
PaperFren

Oncology outcomes

ANXA1 in breast cancer prognosis

Sobral-Leite M, Wesseling J, Smit VT, et al. · BMC medicine · 2015

Open access · cc by · source: Europe PMC

ANXA1-positive breast tumors clustered with poor-prognosis features (high grade, basal/TN, BRCA1/2) and worse outcomes in some high-risk subgroups such as HER2+.

Save to libraryView originalAsk PaperFrenStudy view

Study at a glance

Design
Cohort — Pooled BCAC tumour series plus familial BRCA cases; ANXA1 IHC associations
N
N=5752 · BCAC patients in primary analyses; plus familial BRCA cases in secondary analyses
Population
Women with breast cancer in pooled BCAC cohorts (mostly non-BRCA carriers)
Outcome
ANXA1 associations with tumour subtype markers and breast-cancer-specific survival

Structured fields used in claim comparison tables when every cited study has a complete layer.

Key findings

High-grade tumors had higher ANXA1 odds (OR adj 1.59); ANXA1 linked to basal-like/TN features; HER2+ ANXA1-overexpressing cases had worse 10-year BCSS (HR adj 1.70).

Methodology

Pooled BCAC tumor series (5,752 patients plus familial BRCA cases) assessed ANXA1 expression associations with subtype markers and breast-cancer survival.

Limitations

Does not prove ANXA1 is a ready clinical assay or establish chemotherapy predictive use without further trials.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • SupportsOncology Outcomesconcept

    Multiple studies in this library examine oncology outcomes with empirical patient or population outcomes rather than opinion alone.

    Evidence for the claim as stated.

  • SupportsOncology Outcomesconcept

    High-grade tumors had higher ANXA1 odds (OR adj 1.59); ANXA1 linked to basal-like/TN features; HER2+ ANXA1-overexpressing cases had worse 10-year BCSS (HR adj 1.70).

    Evidence for the claim as stated.

  • SupportsOncology Outcomesconcept

    Effect sizes and settings differ across oncology outcomes studies — digital vs clinic, trial vs observational — so results should not be pooled casually.

    Evidence for the claim as stated.

  • SupportsKaplan-Meier Survival Analysismethod

    A pooled BCAC tumour series (5,752 patients plus familial BRCA cases) related ANXA1 expression to subtype and survival. High-grade tumours had higher ANXA1 odds (adjusted OR 1.59); ANXA1 tracked basal-like/triple-negative features; among HER2-positive cases, ANXA1 overexpression had worse 10-year breast-cancer-specific survival (adjusted HR 1.70). That is an observational biomarker association, not a ready clinical assay or a chemotherapy-predictive trial.

    Evidence for the claim as stated.

  • SupportsKaplan-Meier Survival Analysismethod

    KM in a randomised anaesthetic trial, KM in a biomarker series, KM in a screening cohort, and an 8-week app RCT are not one method applied four times. Propofol versus sevoflurane can say assigned anaesthetic did not shift 5-year OS (~92%, HR near 1). ANXA1's HR 1.70 in HER2-positive overexpression is an observational 10-year BCSS association. NZ ethnic survival gaps change when the sample is restricted to screen-detected cancers. IntelliCare did not analyse cancer death at all.

    Evidence for the claim as stated.

Open questions

Tensions this paper is part of

From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.

Related papers in this topic

Same topic cluster — not a recommendation engine.